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Abstract: Chronic rejection is a major cause of death after the first year following lung trans-
plantation. Bronchiolitis obliterans (BO) is the most common pathologic finding on biopsy, 
characterized by fibrous granulation tissue, which obliterates the lumen of the bronchiole. 
 Clinically, in the absence of tissue for pathology, BO syndrome refers to a progressive irrevers-
ible drop in the forced expiratory volume in 1 second. Recently, a broader definition of chronic 
rejection, termed “chronic lung allograft dysfunction”, has been used to encompass a more 
inclusive definition of posttransplant dysfunction. Recently, the lung transplant community has 
come to realize that chronic rejection may be the final common result after repetitive epithelial 
insults. Acute rejection, infection, and alloreactivity to mismatched HLA antigens are a few 
of these insults that damage the surface of the bronchioles. Recent evidence of autoimmunity 
to the normally hidden structural proteins collagen V and K-α1 tubulin have been correlated 
with a BO phenotype as well, perhaps correlating the epithelial damage with a mechanism for 
developing BO lesions. Many immunomodulatory medications and treatments have been studied 
for effectiveness for the treatment of chronic lung allograft dysfunction. New drugs, which more 
precisely target the immune system, are being developed and tested. Further study is required, 
but recent advances have improved our understanding of the pathogenesis and potential inter-
vention for this common and deadly complication of lung transplantation.
Keywords: lung transplant, bronchiolitis obliterans syndrome, rejection
Introduction
Dr Bruce Reitz performed the first successful heart–lung transplants at Standford 
University (Stanford, CA, USA), in 1981, for idiopathic pulmonary hypertension and 
congenital heart disease.1 Following this achievement, the first single-lung and double-
lung transplant were performed by Dr Joel Cooper in Toronto, ON, Canada, in 1983 
and 1986, respectively.2 Beginning in the mid-1990s, the number of lung transplants 
has increased yearly to a total of 3,640 patients in 2011. From 1994 through 2011, 
the median survival of lung transplant recipients was 5.6 years. Improved survival 
early after lung transplant has resulted in better survival in the most recent era of lung 
transplantation. However, the slope of overall mortality after the first year during the 
most recent era mirrors that of previous eras. Following the first year, the most common 
causes of death are chronic rejection and non-Cytomegalovirus (CMV) infection.3
Chronic lung transplant rejection has classically been described as obliterative bron-
chiolitis (also called bronchiolitis obliterans [BO]). This was first described at Stanford 
in 1984. Of the 19 heart–lung transplants performed for end-stage pulmonary vascular 
disease, 14 patients were long-term survivors. Five of these patients demonstrated a 





typical initial restrictive ventilatory defect on spirometry, 
which improved over the first few months. However, this 
was followed by the development of a progressive obstruc-
tive ventilatory defect with a decline in the forced expiratory 
volume in 1 second (FEV
1
). On biopsy, these patients had 
findings consistent with BO.4
BO develops in a nonuniform pattern and is difficult 
to sample bronchoscopically by transbronchial biopsy. 
 Therefore, the clinical diagnosis of BO syndrome (BOS) is 
used to describe a progressive obstructive ventilatory defect 
without evidence of another explanation (acute rejection, 
infection, airway complication, or other cause). Recently, a 
paradigm shift has occurred in the thinking about chronic 
lung transplant rejection. Namely, BOS is now thought of 
as a large, but specific, form of chronic rejection. The term 
“chronic lung allograft dysfunction” (CLAD) has been 
introduced to include specific forms of allograft dysfunction 
(anastomotic stricture, azithromycin-responsive allograft 
dysfunction, disease recurrence, etc) in addition to a clinical 
description of both obstructive CLAD (BOS) and restrictive 
allograft syndrome (RAS) (Figure 1).5
Throughout this article, we will review the challenges 
inherent to the management of CLAD from diagnosis to 
understanding the pathogenesis and reducing risk factors. 
In addition, we will examine the available treatments for 
CLAD and their efficacy. This review will form a basic 
framework for understanding CLAD and discuss potential 
future solutions for reducing chronic rejection through new, 
more successful treatments.
BOS
BOS is the most common form of CLAD, accounting for 
approximately 70% of cases.6 Pathologically, early BO is 
characterized by lymphocytic inflammation in the submucosa 
of respiratory bronchioles. This leads to late proliferation 
of dense fibromyxoid granulation tissue, which organizes 
to partially or completely fill the lumen of the airway 
(Figure 2).7,8 On biopsy interpretation, these findings are 
denoted as “C1”. These fibrotic lesions are thought to be the 
histologic result of repetitive epithelial injury by multiple 
different insults. However, obtaining sufficient histological 
specimens by transbronchial biopsy documenting these find-
ings is unreliable.9
In the absence of histopathology from a biopsy specimen, 
BOS is more typically diagnosed on routine  spirometry. In 1993, 
the International Society for Heart and Lung Transplantation 
(ISHLT) proposed criteria for the clinical diagnosis of BOS 
based on spirometry (Table 1).  Measurements are made of post-
transplant spirometry. When patients reach a baseline maximal 
FEV
1
 (average of the two best measurements taken at least 3 
weeks apart without administration of bronchodilators), this is 
termed “BOS Stage 0”. Progressive decline in FEV
1
 is staged 
as BOS 1 through 3, with a higher stage indicating a worsened 
obstruction. This schema was updated in 2001 to reflect new 
findings that a drop in FEV
1
 and forced expiratory flow (FEF) 
25%–75% is a more sensitive marker of early obstruction.9,10 
The new BOS stage 0p is defined as a decrease in the FEV
1
 
to ,90% and a decrease in FEF 25%–75% to #75% of the 
posttransplant baseline. It should be noted that, in children, 
by convention, the establishment of a reference value of lung 




Patients may present with nonproductive cough or dysp-
nea on exertion early in the course of BOS. However, patients 
frequently have few complaints, but an asymptomatic decline 
in their FEV
1
 is discovered. In the more advanced stages 
of BOS, symptoms may progress to dyspnea at rest and 
productive cough with evidence of severe obstruction on 
spirometry. In an evaluation of health-related quality of life, 
Gerbase et al prospectively evaluated 58 patients and reported 
a decrease in the St George’s Respiratory Questionnaire 
Figure 1 CLAD Phenotypes.
Notes: Chronic lung allograft dysfunction (CLAD) is a descriptive term for chronic 
lung transplant rejection which encompasses multiple different phenotypes, including 
bronchiolitis obliterans syndrome (BOS), restrictive allograft syndrome (RAS), 
recurrence of primary disease, anastomotic stricture, and azithromycin-responsive 
allograft dysfunction (ARAD), as well as other specific causes of decline in lung 
function.
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(a standardized questionnaire used to measure health and 
perception of well-being11) among patients who developed 
BOS.12 BOS is a major cause of both morbidity and mortality 
among lung transplant recipients. The most recent ISHLT 
data show that, 5 years after transplant, 49% of lung trans-
plant recipients develop BOS, increasing to 76% at 10 years 
(Figure 3).3 One retrospective analysis of actuarial survival 
placed the 3-year mortality after the onset of BOS at 51%.13 
Another study, from Denmark, showed a threefold increased 
risk of death after progression from BOS Stage 1 to Stage 2 
and from BOS Stage 2 to Stage 3.14
When a lung transplant recipient is found to have a drop 
in their FEV
1
, this should be investigated to determine if 
another cause is responsible. Typically, this includes chest 
radiography and bronchoscopy with bronchoalveolar lavage 
(BAL) and transbronchial biopsies. The chest X-ray is not 
a useful tool for screening for early BOS, but is useful 
in establishing a differential diagnosis for the change in 
spirometry. Expiratory chest computed tomography reli-
ably demonstrates air trapping and mosaic attenuation in 
patients with BOS.15,16 However, when using the revised 
criteria to include BOS Stage 0p, which is more effective 
at early detection of BOS, thin-slice computed tomography 
was not helpful in making the diagnosis.17 Bronchoscopy 
should be performed to rule out airway abnormalities and 
infectious causes of declining FEV
1
. Aside from assessing 
Figure 2 Lung biopsy showing bronchiolitis obliterans in the setting of chronic lung transplant rejection.
Notes: Hematoxylin and eosin stain was used.
Table 1 BOS classification
Stage 1994 definition 2001 definition
BOS 0 Fev1 $80% of baseline Fev1 .90% of baseline 
FeF 25%–75% .75% of baseline
BOS 0p Fev1 81%–90% of baseline 
FeF 25%–75% #75% of baseline
BOS 1 Fev1 66%–80% of baseline Fev1 66%–80% of baseline
BOS 2 Fev1 51%–65% of baseline Fev1 51%–65% of baseline
BOS 3 Fev1 #50% of baseline Fev1 #50% of baseline
Abbreviations: BOS, bronchiolitis obliterans syndrome; FeF, forced expiratory 
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Figure 3 Adult lung transplant freedom from bronchiolitis obliterans syndrome 
conditional on survival to 14 days (April 1994–June 2012).
Notes: Reprinted from J Heart Lung Transplant, 32(10), Yusen RD, Christie JD, 
edwards LB, et al; international Society for Heart and Lung Transplantation. The 
Registry of the international Society for Heart and Lung Transplantation: Thirtieth 
Adult Lung And Heart-Lung Transplant Report – 2013; focus theme: age, 965–978, 
Copyright 2013, with permission from elsevier.3





infection, the BAL fluid has been studied to determine its 
utility in predicting onset of BOS. In a retrospective study, 
BAL neutrophilia $20% was a significant predictor for 
BOS Stage 1 or greater in a multivariate regression model. 
Neurohr et al also demonstrated increased IL-8 levels and 
reduced secretory leukocyte protease inhibitor (SLPI) within 
the BAL fluid. These markers were present independent of 
airway bacterial colonization.18 Other studies have demon-
strated elevated levels of other cytokines and inflammatory 
proteins, such as MPO, IL-12, and IL-17; however, it is 
unclear what predictive value these or the presence of airway 
neutrophilia have in the diagnosis of BOS due to multiple 
possible confounding factors.19–21
RAS
While BOS is the most common form of CLAD, increasing 
recognition of a restrictive form of chronic rejection has 
been reported by several centers. This restrictive ventilatory 
defect has been termed “RAS”. The initial report by Sato 
et al, a retrospective review, reports their experience over a 
13-year period. Patients were screened for CLAD by routine 
spirometry and diagnosed when their FEV
1
 declined to ,80% 
of previous baseline. RAS was diagnosed when a follow-up 
total lung capacity (TLC) measurement declined to ,90% 
of baseline. Of the 156 episodes of CLAD diagnosed, 47% 
were characterized as RAS. Patients with RAS had a higher 
incidence of CMV mismatch but were otherwise similar 
regarding donor age, recipient age, primary diagnosis, and 
sex. Most notably, Sato et al discovered that patients with 
RAS had a median survival that was less than half that of 
BOS (541 days versus 1,421 days).6 This definition of RAS 
was limited to bilateral lung transplant recipients only.
These investigators evaluated the progression of RAS 
in a separate study. During this retrospective review, they 
found that RAS, unlike BOS, was characterized by  sporadic 
acute exacerbations and a stepwise decline in FEV
1
 over 
time. Patients primarily presented with symptoms of 
 shortness of breath, fever, and cough during an acute exac-
erbation. The patients they studied had between one and 
four exacerbations, after which they did not recover to their 
baseline FEV
1
. Their outcomes included 32% of patients 
that had a partial recovery, 27% that had stable disease, 
and 41% that had progressive disease. Radiologic findings 
during acute exacerbation were principally characterized 
by asymmetric bilateral ground-glass opacities. However, 
during the period between acute exacerbations, interstitial 
reticular shadows, consolidation, and traction bronchiectasis 
were more often present.22
While definitive pathologic findings have not been 
thoroughly described, initial work from Toronto has demon-
strated consistent findings within the cohort of RAS patients 
described previously. Of the 47 patients diagnosed with RAS, 
16 had histopathologic specimens available for examina-
tion. Fifteen of these sixteen had findings of parenchymal 
fibroelastosis in a subpleural distribution. There were often 
coincident findings of BO and diffuse alveolar damage.23 
Diffuse alveolar damage was the predominant histopatho-
logic finding within the acute exacerbation group described 
previously.22 As a newly described phenomena, the charac-
terization of RAS continues to evolve, but it undoubtedly 
represents a significant and potentially severe posttransplant 
complication.
Risk factors for the  
development of CLAD
Initially, after BOS was recognized to be a major contribu-
tor to posttransplant mortality, work began to determine 
what factors increased the risk of developing this pro-
gressive and, in many cases, untreatable complication. 
In 1998, a report from Heng et al did not show any rela-
tion to sex, age, primary disease, or graft ischemic time. 
Early acute rejection, CMV status, pulmonary infection, 
organizing pneumonia, and human leukocyte antigen 
(HLA) mismatch seemed to be significantly associated 
with onset of BOS.13 A common thread among these risk 
factors may be the immune system’s exposure to injured 
pulmonary epithelium. It has been hypothesized that this 
injury response via alloimmune and autoimmune mecha-
nisms could play a major role in the development of BOS. 
Further delineation of the major risk factors for BOS, pro-
posed underlying mechanisms of injury, and the immune 
system response will be reviewed here.
Acute cellular rejection
An early retrospective investigation by Bando et al identified, 
by multivariate analysis, that three or more episodes of acute 
cellular rejection graded mild to moderate (grade II to III, or 
A2 to A3) or greater significantly increased the risk of devel-
oping BOS.24 Kroshus et al also showed that the cumulative 
number of episodes of acute rejection after 90 days increased 
the relative risk of BOS.25 While these analyses showed that 
moderate-to-severe rejection and multiple episodes of rejec-
tion were risk factors for BOS, Hachem et al26 found that even 
a single episode of early or late minimal (A1) acute cellular 
rejection was associated with a hazard ratio (HR) of 2.64 for 
the development of BOS 1 stage. Khalifah et al showed that 
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a single episode of A2 was associated with more frequent 
progressive BOS.26 Recent work from San Segundo et al 
has demonstrated that an increased number of peripherally 
circulating CD8+ effector T-cells, both pre-transplant and 
during the first year after lung transplant, is associated with 
a higher risk of developing acute rejection.28 Additionally, 
T-cell activity, in the form of granzyme B production and 
other cytokine profiles, has been shown to be elevated in 
lung recipients with acute rejection and prior to or at onset of 
BOS, leading to the concept that physiologic measurements 
and assessments of T-cell function may be a better way of 
monitoring the level of immunosuppression in lung recipients 
than the current method of adjusting medications based on 
serum drug levels.29,30
Lymphocytic bronchiolitis
In 1992, Yousem described submucosal lymphocytic and 
plasma cell infiltration around the airways and deep to the 
smooth muscle layer, which was called lymphocytic bron-
chitis and bronchiolitis (LBB, or B-grade) (Figure 4). This 
lymphocytic infiltrate was present more commonly in patients 
who later went on to develop BO.31 Husain et al showed that 
LBB was, similarly to acute perivascular rejection, associ-
ated with onset of BOS. At 1 year, patients who went on to 
develop BOS had over twice as many episodes of LBB as 
did those without BOS.32
CMV infection
CMV infection is a common infectious complication in the 
posttransplant period in patients with both reactivated or 
donor-derived CMV infection. An initial study by Keenan 
et al, from Pittsburgh, PA, USA, associated BOS with pre-
transplant seropositive status, seropositive donor status, and 
posttransplant CMV infection.33 Further work by Smith et al 
found that CMV mismatch (donor positive/recipient negative) 
may be a risk factor for developing BOS within 3 years of 
transplantation.34 However, other groups have found diverg-
ing data regarding the risk of BOS based on CMV serostatus 
and infection.35–37 Tamm et al reviewed their center’s experi-
ence with CMV pneumonia and CMV serostatus, finding no 
significant differences in development of BOS, and suggested 
that treatment of CMV pneumonia with intravenous ganci-
clovir is protective.38 When ganciclovir is ineffective, such 
as in cases of ganciclovir-resistant CMV, an earlier onset of 
BOS has been reported.39
Non-CMV infections
While CMV pneumonitis is perhaps the most consistently 
implicated infection in the development of BOS, multiple 
studies have evaluated whether other infections are significant 
risk factors. An early study by Hohlfeld et al found that 47% 
of the onset of BOS seemed to cluster in the first quarter of 
the year, January to March, suggesting a possible relationship 
Figure 4 Lung biopsy showing lymphocytic bronchiolitis in the setting of acute lung transplant rejection.
Notes: Hematoxylin and eosin stain was used.





with viral infections.40 Community-acquired respiratory 
viruses ([CARVs] including rhinovirus, coronavirus, respira-
tory syncytial virus, parainfluenza, human metapneumo virus, 
influenza A and B, and adenovirus) have been implicated 
in the development of BOS.41,42 Kumar et al42 reported that 
of nine of 50 patients with a decline in FEV
1
 after CARV 
infection, six had persistent disease classified as BOS. In 
a retrospective review by Khalifah et al, 259 consecutive 
lung transplant patients were found to have 21 episodes of 
CARV infection, which were associated with an HR of 2.05 
for development of BOS Stage 1, and lower respiratory tract 
involvement increased the HR to 3.03.43 This was verified 
prospectively in a mouse model using orthotopic tracheal 
transplant.44 In one series, 0 of 18 patients developed BOS 
after treatment with intravenous ribavirin, suggesting that 
treatment of CARV could prevent the onset of chronic rejec-
tion.45 Other viruses, such as Epstein–Barr virus and human 
herpes virus-6, have also been implicated in the development 
of BOS, though with less supporting evidence.46,47
In addition to viral infection, bacterial and fungal infec-
tions predispose patients to increased rates of BOS as well. 
Valentine et al published their experience, finding that 
Gram-negative, Gram-positive, and fungal pneumonias all 
significantly increased the risk for BOS. In fact, compared 
with uninfected patients, those with bacterial pneumonia 
and fungal pneumonia developed BOS 6 months and 
2 years earlier, respectively.48 Further, not just infection, 
but colonization of the airways seems to be a significant risk 
factor for the development of BOS. Botha et al found that 
Pseudomonas aeruginosa colonization of the airways in lung 
transplant recipients increased the risk of BOS at 2 years 
from 7.7% to 23.4%.49 Similarly, Weigt et al examined the 
effect of Aspergillus spp. colonization on the incidence of 
BOS. Using a multivariate analysis, Aspergillus coloniza-
tion was independently associated with onset and mortality 
due to BOS.50
Primary graft dysfunction (PGD)
PGD is a common early complication after lung transplantation 
manifested by infiltrates that can be seen on chest radiograph 
and impairment of oxygenation. Whitson et al showed 





,200 mmHg) was associated with BOS and a consistently 
lower FEV
1
 at all time points in bilateral lung transplant 
recipients.51 In a retrospective review, Daud et al found that 
PGD was significantly associated with onset of BOS inde-
pendent of acute rejection, lymphocytic bronchiolitis, and 
CARV. With increasing grade of PGD, there was a  progressive 
increase in relative risk for development of BOS (PGD grade 
1=1.68, grade 2=2.04, grade 3=2.61).52
Gastroesophageal reflux (GER)
D’Ovidio et al investigated the hypothesis that GER could 
be a contributing factor for development of BOS. Using 
esophageal pH ,4, they showed that patients with abnormal 
pH had an increased rate of BOS. In addition, they corre-
lated presence of bile acid and subsequent decreased levels 
of surfactant protein A in the BAL fluid.53 Blondeau et al54 
found that both pepsin and bile acid were routinely found 
in the BAL of lung transplant recipients. However, they did 
not find a correlation with GER, but instead an association 
with both acid and non-acid reflux, suggesting this could 
be the true risk factor for BOS. In a single center study, 
Cantu et al described a strategy for surgical treatment, via 
fundoplication, for lung transplant patients. At their center, 
all transplant candidates are screened with esophageal pH 
monitoring and surgery is performed posttransplant for any 
patient with evidence of reflux and without a contraindica-
tion. Their retrospective review evaluated the results of these 
efforts over time. Of 202 patients screened for reflux, 85 had 
either early (average time after transplant =43 days) or late 
(average time after transplant =684 days) surgical treatment 
aimed at control of reflux. Freedom from BOS at 1 year was 
observed in 100% of those with early surgery (n=14), com-
pared with 91% of those without reflux (n=180) and 92% of 
those in the late surgery group (n=62). At 3 years, that differ-
ence was greater: freedom from BOS was 100% in the early 
surgery group (n=5), compared with 62% in those without 
reflux (n=93) and 47% in the late surgery group (n=30).55 
The benefit of surgical correction of GER in asymptomatic 
lung transplant recipients is an ongoing area of investigation; 
there remains no consensus between transplant centers on 
the use of fundoplication for GER in lung recipients. The 
preliminary data from the multicenter Reflux Surgery in 
Lung Transplantation (RESULT) study was presented at the 
ISHLT meeting in April 2014 and, at that time, did not reveal 
any significant benefit to fundoplication. The final report of 
this study is pending at this time.56
HLA mismatching
Given the hypothesis of alloimmune activation as a primary 
cause for CLAD, HLA mismatch between donor and recipient 
has been extensively studied. Previous studies in heart and 
kidney transplantation revealed that HLA mismatch was a 
significant risk factor for graft loss.57,58 Single-center studies 
revealed an association between both HLA class I (HLA-A) 
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and class II (HLA-DR) mismatches and  development 
of BOS.59,60 A large, United Network for Organ Sharing 
(UNOS)/ISHLT database study revealed a significant increase 
in the risk of acute rejection and graft failure associated with 
HLA-A and HLA-DR, but, due to limited follow-up, did not 
find a significant increase in the rate of BOS.58 Many other 
contradictory studies, which make this risk less clear, have 
also been published.13,35,60
The evidence is more consistent in the study of anti-HLA 
antibodies that develop posttransplant. Sundaresan et al 
showed this was a much stronger signal for development of 
BOS than HLA-A mismatch at the time of transplantation.59 
These results have been duplicated  as well.61 Improvement 
in the sensitivity of diagnostic techniques has allowed for 
better detection of anti-HLA antibodies and increased abil-
ity to correlate those results with BOS.62 Previous work 
by Jaramillo et al has demonstrated that anti-HLA class I 
antibodies trigger the activation and proliferation of airway 
epithelial cells as well as production of growth factors, 
fibroblast proliferation, and apoptosis.63
Further work by Hachem et al examined the development 
of donor-specific anti-HLA antibodies (DSA) in a single-
center prospective trial. Of the 116 patients examined, 56% 
developed DSA (15% class I, 63% class II, 22% both classes). 
This study was designed to examine the effect of treatment for 
DSA with either intravenous immunoglobulin (IVIG) or IVIG 
plus rituximab on the development of antibody-mediated 
acute and chronic rejection. They found that, irrespective 
of the treatment received, patients that cleared their DSA 
after treatment had a lower incidence of BOS and prolonged 
survival compared to those with persistent DSA.64 Newer 
modalities of therapy for antibody-mediated rejection and 
depletion of anti-HLA antibodies have been studied more 
extensively in kidney transplantation, including bortezomib, 
a 26S proteasome inhibitor that can block NF-κB signaling 
within mature plasma cells.65
Non-HLA autoimmune response
In addition to the alloimmune response to donor HLA, 
increased risk of BOS due to a similar autoimmune response 
has been observed in non-HLA antibodies such as collagen V 
and K-α1 tubulin.66,67 Specifically, these anti-airway epithe-
lial cell antibodies have been found in up to 31% of lung 
transplant recipients with BOS. Downstream signaling 
via increased calcium influx leads to cell proliferation and 
increased transcription of fibrogenic growth factors, similar 
to the anti-HLA response.68 This autoimmune activation 
seems to be mediated by a Th17 response.69 Other labs have 
also shown that a failure of maturation of regulatory T cells 
may contribute to the autoimmune reaction seen in chronic 
lung transplant rejection.70
Treatment
Typical immunosuppression for lung transplant recipients 
includes a calcineurin inhibitor, a purine synthesis inhibi-
tor, and a corticosteroid. Based on the major risk factors for 
CLAD identified to date, it is clear that immunosuppression 
plays a major role in its prevention. Aside from ensuring 
adequate dosing and blood levels of immunosuppressive 
drugs, a switch between these drugs has been shown to poten-
tially treat BOS. In one of the first trials to assess the change 
in pulmonary function when switching from cyclosporine to 
tacrolimus, Cairn et al showed that, in patients with BOS, 
the rate of decline in FEV
1
 and FEF 25%–75% decreased 
significantly in the 70% of patients that responded.71 Hachem 
et al conducted a randomized controlled trial to evaluate the 
outcomes after treating patients with one of the calcineurin 
inhibitors, either cyclophosphamide or tacrolimus. There 
was a nonstatistically significant decline in the occurrence of 
BOS in the tacrolimus group compared to the cyclosporine 
group.72 Similar stabilization of spirometry has also been 
shown when switching from azathioprine to mycophenolate 
mofetil.73 Other immunosuppressive agents, such as metho-
trexate and cyclophosphamide, have also been studied in 
small case series with successful stabilization of FEV
1
.74,75 
However, given their potentially severe side effects, they have 
not gained wide acceptance.
Aerosolized cyclosporine and tacrolimus have also been 
studied to try to maximize drug delivery to the lungs while 
minimizing toxicity.76–78 Initially, cyclosporine was studied 
as a means of reducing acute rejection; however, Iacono et al 
noted increased chronic rejection-free survival instead.78 The 
follow-up study by Groves et al, which randomized patients 
to inhaled cyclosporine versus inhaled placebo, determined 
that, in addition to standard immunosuppression, inhaled 
cyclosporine yielded improved FEV
1
 and FEF 25%–75%.76
The macrolide antibiotic azithromycin has been exten-
sively studied for the treatment and prevention of CLAD. 
An initial pilot study of six patients demonstrated that, after 
initiation of azithromycin, five of six had improvement in 
FEV
1
 of approximately 17% of predicted values.79 Yates et al 
used azithromycin to treat BOS in 20 patients, resulting in 
a mean improvement in FEV
1
 of 110 mL at 3 months. This 
improvement was maintained in 12 of the 17 patients that 
showed initial improvement.80 Further evidence suggests that 
a survival advantage is obtained when starting  azithromycin 





during BOS Stage 1, rather than BOS at stages higher than 
Stage 1.81 Attempting to determine a predictive model in 
which patients will benefit from azithromycin therapy, 
Verleden et al found that responders had a significantly higher 
pretreatment BAL neutrophilia and elevated IL-8 mRNA 
levels.82 Azithromycin has also been investigated for preven-
tion of BOS in a randomized controlled trial at the Leuven 
University Hospital (Leuven, Belgium). Over 2 years, BOS 
occurred less frequently in those on azithromycin (12.5%) 
versus those on placebo (44.2%).83
Newer antiproliferative agents such as sirolimus and 
everolimus have been investigated for their unique mecha-
nism of action. Typically, they are substituted for aza-
thioprine, as in the study by Hachem et al, who made the 
substitution after patients developed a composite endpoint 
of cumulative acute rejection, lymphocytic bronchiolitis, or 
BOS.72 While these patients had a decrease in their cumula-
tive acute rejection score, they did not have less incidence 
of lymphocytic bronchiolitis or BOS. In fact, approximately 
60% of patients had to discontinue therapy due to adverse 
reaction. In another study, Roman et al found improved renal 
insufficiency but no change in FEV
1
 in patients who were 
converted to everolimus from either a calcineurin inhibitor 
or a purine synthesis inhibitor.84
Immunodepleting and cytotoxic therapies have also 
been investigated. Anti-thymocyte globulin, which depletes 
circulating T-cells, was found to slow the decline of FEV
1
 
over the first 3 months after treatment. However, in all but 
two cases, BOS ultimately progressed.85 Alemtuzumab, an 
anti-CD52 antibody, was studied in the setting of refractory 
acute rejection by Reams et al. CD52 is a surface protein 
expressed on B-cells, T-cells, monocytes, macrophages, and 
platelets. Their study observed ten patients with BOS who had 
previously failed increased prednisone and anti-thymocyte 
globulin. Four of the ten patients had improved FEV
1
. 
However, during the study, 73% of patients experienced an 
infectious complication.86
While medications to modify the immune system rep-
resent the majority of the treatments that have been used 
for BOS, certain procedures to modify the immune system 
have also been studied. One such therapy is extracorporeal 
photopheresis (ECP). This procedure involves administer-
ing 8-methoxypsoralen, performing leukapheresis through 
an extracorporeal circuit, exposure of these leukocytes to 
ultraviolet A light, and infusing the leukocytes back into the 
patient. DNA in the leukocytes is cross-linked by the ultra-
violet A light, though this only affects 2%–5% of the periph-
eral leukocytes per treatment. Other proposed  mechanisms 
by which ECP works include a release of  inflammatory 
mediators, apoptosis of peripheral T-cell populations, and, 
most importantly, the production of a suppressor T-cell 
response and induction of immune tolerance.87 Preliminary 
reports showed that ECP can stabilize the decline in FEV
1
 
in some patients who were refractory to all other available 
treatments.87,88 Based on reports from Meloni et al, respond-
ers to ECP tend to have increased circulating T-regulatory 
cells in response to  treatment.89 In the largest study to date, 
Morrell et al1 showed that, after initiation of ECP, rate of 
decline in FEV
1
 slowed and stabilized with minimal related 
 complications. Other nonpharmacological therapies, such as 
total lymphoid irradiation, were initially successful in small 
series of patients, but there was significant drop out due to 
progressive BOS or bone marrow suppression.90,91
Treatments for RAS mirror the treatments for BOS 
descried as above. While understanding of the risk factors 
and underlying immune response for BOS has slowly pro-
gressed, the questions regarding the etiology of RAS are 
even more numerous. In initial studies, neither augmented 
corticosteroids nor antibiotics showed improved survival for 
patients with RAS.22 Other investigators have attempted to 
use drugs being investigated for pulmonary fibrosis, such as 
pirfenidone, for treatment, with little success.92
The last line of treatment for refractory CLAD is repeat lung 
transplantation. However, ethical questions regarding the appro-
priateness of retransplantation in the setting of large waiting 
lists for first-time transplantation have been raised. In addition, 
early data from a pulmonary retransplant registry showed worse 
survival and earlier onset of BOS compared with first-time 
lung transplants.1,93 More recently, Hayes reviewed analyses 
of retransplantation and found a comparable 1-year and 5-year 
survival rates.94 The role of retransplantation as a treatment for 
chronic lung allograft dysfunction remains controversial and 
policies vary by center on the frequency of its use.
Conclusion
CLAD is the most common cause of death among lung 
transplant recipients after the first year. Through 3 decades 
of experience, the rate of mortality within the first year after 
transplantation has decreased. While there are still many 
unanswered questions regarding the development of chronic 
lung transplant rejection, recognition of subgroups within 
CLAD allows more specific pathophysiologic investigations 
and the potential to develop effective treatment modalities 
for patients as we begin to practice precision medicine. With 
the  knowledge accumulated over time, the major risk factors 
for the development of chronic rejection have been clarified, 
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a greater understanding of the immunobiology related to the 
progression of CLAD has been achieved, and new immuno-
modulatory treatments have been developed to take advantage 
of knowledge gained. We can imagine that, in the decades to 
come, CLAD will become better understood and that newer, 
more precise therapies will be implemented, allowing lung 
transplant recipients to enjoy longer survival than those lung 
recipients who have gone before them.
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